DSP-5336, an Investigational Menin and Mixed-lineage Leukemia Inhibitor, is Being Evaluated in Patients with Relapsed or Refractory Acute Leukemia
Nadda expressed his concern about growing incidence of Non-Communicable Diseases and the importance of awareness regarding healthy diet and lifestyle
Private financing round supported by Fidelity Management & Research Company, T. Rowe Price and Durable Capital Partners
The Gavi Board today approved the Vaccine Alliance's strategy for the five-year period running from 2026 to 2030
Facility in The Woodlands, Texas to produce critical starting material for cell and gene therapy, DNA/RNA-based, and recombinant protein therapeutics in Q1/2025
Greg was also central to the planning, design, and construction of this facility
Largest investment in active pharmaceutical ingredient manufacturing of synthetic medicines in U.S. history
Further strengthens BaseLaunch's global pharma industry partnerships
Phase I data for tuvusertib, lead asset from the company’s unique portfolio of DDR inhibitors
Cresset’s new India site will support the growing demands of Cresset’s APAC customer base
Subscribe To Our Newsletter & Stay Updated
